Mount Yale Investment Advisors LLC Trims Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Mount Yale Investment Advisors LLC decreased its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 62.1% in the fourth quarter, Holdings Channel reports. The firm owned 5,673 shares of the biopharmaceutical company’s stock after selling 9,305 shares during the period. Mount Yale Investment Advisors LLC’s holdings in Halozyme Therapeutics were worth $271,000 at the end of the most recent quarter.

A number of other hedge funds also recently added to or reduced their stakes in HALO. Mercer Global Advisors Inc. ADV acquired a new stake in Halozyme Therapeutics in the second quarter valued at approximately $182,000. AQR Capital Management LLC grew its position in shares of Halozyme Therapeutics by 5.0% in the second quarter. AQR Capital Management LLC now owns 47,773 shares of the biopharmaceutical company’s stock valued at $2,501,000 after purchasing an additional 2,265 shares during the period. Mackenzie Financial Corp increased its position in shares of Halozyme Therapeutics by 42.3% during the second quarter. Mackenzie Financial Corp now owns 14,779 shares of the biopharmaceutical company’s stock worth $774,000 after purchasing an additional 4,393 shares in the last quarter. Susquehanna Fundamental Investments LLC acquired a new stake in shares of Halozyme Therapeutics in the second quarter valued at about $209,000. Finally, Algert Global LLC acquired a new stake in shares of Halozyme Therapeutics in the second quarter valued at approximately $670,000. 97.79% of the stock is owned by hedge funds and other institutional investors.

Halozyme Therapeutics Stock Down 0.3 %

Shares of NASDAQ HALO opened at $55.83 on Thursday. Halozyme Therapeutics, Inc. has a 1 year low of $33.15 and a 1 year high of $65.53. The firm’s 50 day moving average price is $50.28 and its 200 day moving average price is $54.28. The company has a debt-to-equity ratio of 3.32, a quick ratio of 9.15 and a current ratio of 10.36. The firm has a market cap of $7.10 billion, a P/E ratio of 18.49, a price-to-earnings-growth ratio of 0.42 and a beta of 1.24.

Insider Activity at Halozyme Therapeutics

In related news, Director Jeffrey William Henderson sold 10,000 shares of Halozyme Therapeutics stock in a transaction on Monday, January 6th. The stock was sold at an average price of $50.01, for a total value of $500,100.00. Following the transaction, the director now owns 43,611 shares in the company, valued at approximately $2,180,986.11. This trade represents a 18.65 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 2.40% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. HC Wainwright boosted their price target on shares of Halozyme Therapeutics from $68.00 to $70.00 and gave the company a “buy” rating in a research note on Friday, January 10th. Piper Sandler boosted their price target on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a research report on Friday, January 10th. Cowen reissued a “buy” rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. JMP Securities boosted their price target on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a research note on Friday, November 1st. Finally, Wells Fargo & Company decreased their price target on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $60.89.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.